Regeneron (REGN) Misses Q1 EPS by 101c, Revenues Miss; Provides FY19 Operating Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron Reports First Quarter 2019 Financial and Operating Results
May 7, 2019 6:30 AM EDTTARRYTOWN, N.Y., May 7, 2019 /PRNewswire/ -- Â
First quarter 2019 revenues increased 13% to $1.71 billion versus first quarter 2018 First quarter 2019 EYLEA® (aflibercept) Injection U.S. net sales increased 9% to $1.07 billion versus first quarter 2018 First quarter 2019 EYLEA net sales outside the United States, which are recorded by the Company's collaborator Bayer(1), increased 7% to $669 million versus first quarter 2018 First quarter 2019 Dupixent® (dupilumab) global net sales, which are recorded by the Company's collaborator Sanofi, were $374 million First quarter 2019 Libtayo® (cemiplimab) U.S. net sales were $27... More